Analysts at Susquehanna downgraded Transocean Ltd. (RIG) from ‘Neutral‘ to ‘Negative‘ in a research report issued to clients on Monday.
The target price for RIG is lowered from $15 to $12.
On valuation measures, Transocean Ltd. stock it is trading at a forward P/E multiple of 7.81x, and P/E to growth ration of (0.09).
The T-twelve-month revenue at Transocean Ltd. is $9.42B. RIG ‘s ROE for the same period is (6.13%).
Shares of the $5.87B market cap company are down 57.84% year-over-year, and 7.20% year-to-date.
RIG, currently with a median Wall Street price target of $15.00 and a high target of $35.00, dropped $0.81 to $16.2032 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
Polypore International Inc. (PPO) was downgraded from ‘Buy‘ to ‘Hold‘ while the price target was raised from $54 to $60.50 at Topeka Capital Markets.
Shares have traded today between $59.27 and 59.88 with the price of the stock fluctuating between $29.59 to 59.88 over the last 52 weeks.
Polypore International Inc. shares are currently changing hands at 41.09x this year’s forecasted earnings, compared to the industry’s 17.18x earnings multiple. Ticker has a t-12 price/sales ratio of 3.57. EPS for the same period registers at $1.45.
Shares of PPO have gained $6.76 to $59.71 in mid-day trading on Monday, giving it a market cap of roughly $2.67B. The stock traded as high as $59.88 in November 6, 2014.
Compass Point reported on Monday that they have lowered their rating for Home Loan Servicing Solutions, Ltd. (HLSS). The firm has downgraded HLSS from ‘Buy‘ to ‘Neutral‘.
As for passive income investors, the company pays shareholders $2.16 per share annually in dividends, yielding 13.40%.
Home Loan Servicing Solutions Ltd. recently traded at $18.34, a gain of $1.58 over Friday’s closing price. The name has a current market capitalization of $1.30 billion.
Salix Pharmaceuticals Ltd. (SLXP) had its rating lowered from ‘Outperform‘ to ‘Market Perform‘ by analysts at Leerink Partners on Monday.
SLXP was down $1.96 at $155.89 in mid-day trade, moving within a 52-week range of $86.00 to $172.98. The name, valued at $9.93B, opened at $156.35.
On valuation measures, Salix Pharmaceuticals Ltd. shares have a t-12 price/sales ratio of 7.30. EPS for the same period registers at ($1.22).
CyberArk Software, Ltd. (CYBR) was downgraded by JP Morgan (JPM) from a ‘Neutral‘ rating to a ‘Underweight‘ rating in a research report issued to clients on Monday.
CYBR closed at $70.35 on Friday and is currently trading down $11.60.
In the past 52 weeks, shares of the company have traded between a low of $22.12 and a high of $70.48 and are now trading at $58.79. Shares are up 98.66% year-over-year, and 49.97% year-to-date.